Spinamycin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-02928 |
| CAS | 25375-16-0 |
| Molecular Weight | 286.33 |
| Molecular Formula | C16H18N2O3 |
Online Inquiry
Description
It is an aromatic derivative of antibiotic produced by the strain of Str. albospinus M-750-G1. It has anti-mycobacterium and fungal effects, and the serum does not affect its effect on Cryptococcus yeast and psoriasis mold. It inhibits cell culture for Yoshida sarcoma with IC50 of 1.5 μg/mL. Mice can tolerate 125 mg/kg of Spinamycin intraperitoneal injection.
Specification
| Related CAS | 11005-60-0 |
| Synonyms | Succinic acid, 2-(m-(1,3,5-hexatrienyl)phenyl)hydrazide; Succinic acid, mono(2-(m-1,3,5-hexatrienylphenyl)hydrazide); Butanedioic aid, mono(2-(3-(1,3,5-hexatrienyl)phenyl)hydrazide) |
| IUPAC Name | 2-(1,3-dihydroxypropan-2-yl)-6-[(1E,3E)-hexa-1,3,5-trienyl]-N-iminobenzamide |
| Canonical SMILES | C=CC=CC=CC1=C(C(=CC=C1)C(CO)CO)C(=O)N=N |
| InChI | InChI=1S/C16H18N2O3/c1-2-3-4-5-7-12-8-6-9-14(13(10-19)11-20)15(12)16(21)18-17/h2-9,13,17,19-20H,1,10-11H2/b4-3+,7-5+,18-17? |
| InChI Key | HYIIDAABDYGOAY-PORXBIHVSA-N |
Properties
| Appearance | Colorless Acicular Crystal |
| Antibiotic Activity Spectrum | Neoplastics (Tumor); Fungi; Mycobacteria |
| Boiling Point | 498.0°C at 760 mmHg |
| Melting Point | 143°C |
| Density | 1.12 g/cm3 |
| Solubility | Soluble in Methanol, Chloroform, Ethanol |
Reference Reading
1. A fresh look at the role of spiramycin in preventing a neglected disease: meta-analyses of observational studies
Jose G Montoya, Katherine Laessig, Mir Sohail Fazeli, Gaye Siliman, Sophie S Yoon, Elizabeth Drake-Shanahan, Chengyue Zhu, Akbar Akbary, Rima McLeod Eur J Med Res. 2021 Dec 11;26(1):143. doi: 10.1186/s40001-021-00606-7.
Purpose: We aimed to investigate the effect of antepartum treatment with spiramycin with or without subsequent pyrimethamine-sulfonamide-folinic acid, compared to no treatment, on the rate of mother-to-child transmission (MTCT) of Toxoplasma gondii (T. gondii) and incidence/severity of sequelae in the offspring. Methods: Embase and PubMed were searched for literature on spiramycin in pregnant women suspected/diagnosed with T. gondii infection. Meta-analyses were performed using random-effects model. Results: Thirty-three studies (32 cohorts and 1 cross-sectional study), with a total of 15,406 mothers and 15,250 offspring, were pooled for analyses. The MTCT rate for all treated patients was significantly lower than the untreated [19.5% (95% CI 14-25.5%) versus 50.7% (95% CI 31.2-70%), p < 0.001]. The transmission rate in patients on spiramycin monotherapy was also significantly lower than untreated [17.6% (95% CI 9.9-26.8%) versus 50.7% (95% CI 31.2-70%), p < 0.001]. Conclusion: Results indicate significant reduction in MTCT rates following spiramycin treatment of suspected/diagnosed maternal T. gondii infection.
2. The regulatory genes involved in spiramycin and bitespiramycin biosynthesis
Jianlu Dai, Yiguang Wang, Juanjuan Liu, Weiqing He Microbiol Res. 2020 Nov;240:126532. doi: 10.1016/j.micres.2020.126532. Epub 2020 Jun 27.
Bitespiramycin (biotechnological spiramycin, Bsm) is a new 16-membered macrolide antibiotic produced by Streptomyces spiramyceticus WSJ-1 integrated exogenous genes. The gene cluster for Bsm biosynthesis consists of two parts: spiramycin biosynthetic gene cluster (92 kb) and two exogenous genes including 4"-O-isovaleryltransferase gene (ist) and a positive regulatory gene (acyB2) from S. thermotolerans. Four putative regulatory genes, bsm2, bsm23, bsm27 and bsm42, were identified by sequence analysis in the spiramycin gene cluster. The inactivation of bsm23 or bsm42 in S. spiramyceticus eliminated spiramycin production, while the deletion of bsm2 and bsm27 did not abolish spiramycin biosynthesis. The acyB2 gene, homologous with bsm42 gene, cannot recover the spiramycin production in Δbsm42 mutant. The high expression of bsm42 significantly increased the spiramycin production, but overexpression of bsm23 inhibited its production in Δbsm23 and wild-type strain. Bsm23 was shown to be involved in the regulation of the expression of bsm42 and acyB2 by electrophoretic mobility shift assays. The bsm42 gene was also positive regulator for ist expression inferred from the improved yield of 4"-isovalerylspiramycins in the S. lividans TK24 biotransformation test, but adding bsm23 decreased the production of 4''-isovalerylspiramycins. These results demonstrated Bsm42 was a pathway-specific activator for spiramycin or Bsm biosynthesis, but overexpression of Bsm23 alone was adverse to produce these antibiotics although Bsm23 was essential for positive regulation of spiramycin production.
3. Anti-Inflammatory Effects of Spiramycin in LPS-Activated RAW 264.7 Macrophages
Jin-Kyu Kang, Hyun-Kyu Kang, Chang-Gu Hyun Molecules. 2022 May 17;27(10):3202. doi: 10.3390/molecules27103202.
Drug repurposing is a simple concept with a long history, and is a paradigm shift that can significantly reduce the costs and accelerate the process of bringing a new small-molecule drug into clinical practice. We attempted to uncover a new application of spiramycin, an old medication that was classically prescribed for toxoplasmosis and various other soft-tissue infections; specifically, we initiated a study on the anti-inflammatory capacity of spiramycin. For this purpose, we used murine macrophage RAW 264.7 as a model for this experiment and investigated the anti-inflammatory effects of spiramycin by inhibiting the production of pro-inflammatory mediators and cytokines. In the present study, we demonstrated that spiramycin significantly decreased nitric oxide (NO), interleukin (IL)-1β, and IL-6 levels in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. Spiramycin also inhibited the expression of NO synthase (iNOS), potentially explaining the spiramycin-induced decrease in NO production. In addition, spiramycin inhibited the phosphorylation of mitogen-activated protein kinases (MAPKs); extracellular signal-regulated kinase (ERK) and c-Jun N terminal kinase (JNK) as well as the inactivation and subsequent nuclear translocation of nuclear factor κB (NF-κB). This indicated that spiramycin attenuates macrophages' secretion of IL-6, IL-1β, and NO, inducing iNOS expression via the inhibition of the NF-κB and MAPK signaling pathways. Finally, we tested the potential application of spiramycin as a topical material by human skin primary irritation tests. It was performed on the normal skin (upper back) of 31 volunteers to determine whether 100 μM and μM of spiramycin had irritation or sensitization potential. In these assays, spiramycin did not induce any adverse reactions. In conclusion, our results demonstrate that spiramycin can effectively attenuate the activation of macrophages, suggesting that spiramycin could be a potential candidate for drug repositioning as a topical anti-inflammatory agent.
Recommended Products
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
| BBF-03754 | CASTANOSPERMINE | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
